Welcome to our dedicated page for Biogen SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biogen Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company with commercial products and development programs in neurology, rare disease and immune-mediated conditions. Forms 8-K cover operating and financial results, product-revenue commentary, acquired in-process research and development, upfront and milestone expenses, collaboration and license-agreement costs, material agreements, capital-structure disclosures and clinical or regulatory updates.
Biogen’s proxy and governance filings address board leadership, director matters, executive compensation and annual meeting items. The filing record also documents the company’s common stock registered on The Nasdaq Global Select Market, officer and director transitions, risk-related forward-looking disclosures and transaction communications tied to strategic business development activity.
BIOGEN INC. director William A. Hawkins reported an equity compensation award rather than an open-market trade. He acquired 1,505 shares of Common Stock at no cost under a grant classified as a “grant, award, or other acquisition.”
After this award, Hawkins directly holds 10,365 Common Stock shares. According to a footnote, the related restricted stock units vest on the earlier of the next annual meeting or the anniversary of the date of grant of June 9, 2026, tying this award to his ongoing board service.
SHERWIN STEPHEN A reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. director Stephen A. Sherwin reported receiving an equity award of 1,505 shares of common stock on June 9, 2026, at no cash cost to him, as a grant or award. Following this grant, he holds a total of 15,193 common shares directly.
The award consists of restricted stock units that will vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date, tying the compensation to his continued board service over this period.
Rowinsky Eric K reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. director Eric K. Rowinsky received an equity grant as part of his compensation. He was awarded 1,505 shares of common stock in the form of restricted stock units at a grant price of $0.00 per share.
After this grant, he directly holds 25,844 shares of Biogen common stock. The restricted stock units vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date, tying his compensation to the company’s future performance over roughly a one-year period.
Mantas Jesus B reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. director Jesus B. Mantas reported an equity award of 1,505 shares of Common Stock, received as a grant rather than a market purchase. Following this award, his direct ownership increased to 11,263 shares.
The filing notes that the associated restricted stock units vest on the earlier of the company’s next annual meeting or the anniversary of the June 9, 2026 grant date, tying the award to continued board service over that period.
LANGER SUSAN reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. director Susan Langer received a grant of 1,505 shares of common stock as a compensation award. The grant was recorded at a price of $0.00 per share, indicating it was not an open-market purchase. After this award, she directly holds 6,634.1 common shares. A footnote explains that the restricted stock units from this grant vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date, tying the award’s vesting to the company’s governance calendar.
Patolawala Monish D reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. director Monish D. Patolawala received an equity grant of 1,505 shares of Common Stock as a compensation award at no cost. Following this award, he directly holds 5,215 shares. The restricted stock units vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date.
BIOGEN INC. director Menelas N. Pangalos reported routine equity compensation activity. He received a grant or award of 1,505 shares of Common Stock at a stated price of $0.00 per share, reflecting stock-based director compensation rather than an open-market purchase.
On the same date, he exercised 2,370 Restricted Stock Units into 2,370 shares of Common Stock, fully settling that RSU award. Following these transactions, his direct holdings of Biogen common stock increased to 3,875 shares. Footnotes state that the restricted stock units vest upon the earlier of the next annual meeting or the first anniversary of their respective grant dates.
Minor Lloyd reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. director Lloyd Minor received an equity award of 1,505 restricted stock units. These units were granted at no cash cost and increase his direct holdings to 3,875 shares of common stock. The restricted stock units vest on the earlier of the next annual meeting or the June 9, 2026 grant anniversary.
Freire Maria C reported acquisition or exercise transactions in this Form 4 filing.
Biogen director Maria C. Freire received an equity award of 2,005 shares of common stock in the form of restricted stock units. The grant carried no purchase price and represents compensation rather than an open-market trade. Following this award, she directly owns 8,820 shares of Biogen common stock. The restricted stock units vest on the earlier of the next annual meeting or the June 9, 2026 anniversary of the grant date.
Biogen Inc. reported the voting results from its 2026 Annual Meeting of Stockholders held on June 9, 2026. Stockholders voted on the election of directors and other proposals. Director nominees, including Christopher A. Viehbacher and Lloyd Minor, each received substantially more votes "For" than "Against," with notable support such as 121,127,966 votes "For" for Mr. Viehbacher and 121,220,738 votes "For" for Dr. Minor. One proposal received 124,551,887 votes "For" versus 6,627,086 "Against," while another proposal received 114,184,816 votes "For" and 7,454,737 "Against," along with broker non-votes.